Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for tough liver cancers: Nerve-Blocking technique added to standard therapy

NCT ID NCT07187284

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 21 times

Summary

This study tests whether adding a nerve-blocking procedure (endovascular denervation) to standard treatments (TACE/HAIC and immune-targeted therapy) can help people with advanced liver cancer that has spread to the portal vein. The cancer must have gotten worse after initial treatment. About 62 adults will be randomly assigned to get the new combination or standard care alone. The goal is to see if the combination slows cancer growth in the liver and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zhongda Hospital Affiliated to Southeast University, Department of Interventional and Vascular Surgery

    Nanjing, Jiangsu, 210009, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.